A5025085620- Peripheral Neuropathies and Disorders
- Hereditary Neurological Disorders
- Myasthenia Gravis and Thymoma
- Amyotrophic Lateral Sclerosis Research
- Inflammatory Myopathies and Dermatomyositis
- Botulinum Toxin and Related Neurological Disorders
- Pain Mechanisms and Treatments
- Muscle Physiology and Disorders
- Peripheral Nerve Disorders
- Neurogenetic and Muscular Disorders Research
- Parkinson's Disease and Spinal Disorders
- Cancer Treatment and Pharmacology
- Genetic Neurodegenerative Diseases
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Retinal Diseases and Treatments
- Myofascial pain diagnosis and treatment
- Skin Diseases and Diabetes
- Glaucoma and retinal disorders
- Folate and B Vitamins Research
- Neurological and metabolic disorders
- Nerve injury and regeneration
- Platelet Disorders and Treatments
- Musculoskeletal pain and rehabilitation
- Alcoholism and Thiamine Deficiency
- Parkinson's Disease Mechanisms and Treatments
University of Arizona
2008-2024
University of Kansas Medical Center
2002-2023
New England Retina Associates
2023
Arizona Research Center
2023
Phoenix Neurological Associates
2011-2020
Patient-Centered Outcomes Research Institute
2020
HonorHealth
2019
University of California, Irvine
2016-2018
University at Buffalo, State University of New York
2018
California Pacific Medical Center
2018
Abstract Dermatomyositis has been modeled as an autoimmune disease largely mediated by the adaptive immune system, including a local humorally response with B and T helper cell muscle infiltration, antibody complement‐mediated injury of capillaries, perifascicular atrophy fibers caused ischemia. To further understand pathophysiology dermatomyositis, we used microarrays, computational methods, immunohistochemistry electron microscopy to study specimens from 67 patients, 54 inflammatory...
To characterize an acquired, symmetric, demyelinating neuropathic variant with distal sensory or sensorimotor features.Classic chronic inflammatory polyradiculoneuropathy (CIDP) patients have prominent proximal and weakness. However, neuropathies may present different phenotypes. An approach that distinguishes these disorders primarily according to the pattern of weakness be useful clinician.A total 53 acquired symmetric polyneuropathies were classified neuropathy secondarily presence type...
We report 11 patients with multifocal acquired demyelinating sensory and motor (MADSAM) neuropathy, defined clinically by a pattern of loss, nerve conduction studies showing block other features demyelination. The clinical, laboratory, histological these were contrasted those 16 neuropathy (MMN). Eighty-two percent MADSAM had elevated protein concentrations in the cerebrospinal fluid, compared 9% MMN (P < 0.001). No patient anti-GM1 antibody titers, 56% 0.01). In contrast to subtle...
To determine the steroid-sparing effect of methotrexate (MTX) in patients with symptomatic generalized myasthenia gravis (MG).We performed a 12-month multicenter, randomized, double-blind, placebo-controlled trial MTX 20 mg orally every week vs placebo 50 acetylcholine receptor antibody-positive MG between April 2009 and August 2014. The primary outcome measure was prednisone area under dose-time curve (AUDTC) from months 4 to 12. Secondary measures included changes Quantitative Myasthenia...
Background: Chronic sensory-predominant polyneuropathy (PN) is a common clinical problem confronting neurologists.Even with modern diagnostic approaches, many of these PNs remain unclassified.Objective: To better define the and laboratory characteristics large group patients cryptogenic sensory (CSPN) evaluated in 2 university-based neuromuscular clinics.Design: Medical record review for PN during 2-year period.We defined CSPN on basis pain, numbness, tingling distal extremities without...
<b><i>Objective:</i></b> To describe a sporadic motor neuron disorder that remains largely restricted to the upper limbs over time. <b><i>Background:</i></b> Progressive amyotrophy is isolated in an adult often suggests ALS. The fact weakness can remain confined arms for long periods of time individuals presenting with this phenotype has not been emphasized. <b><i>Methods:</i></b> We reviewed records patients who had neurogenic “man-in-the-barrel” documented by examination at least 18 months...
Diagnosing cobalamin (Cbl) deficiency as a cause of polyneuropathy (PN) is problematic, the frequency both disorders increases with age, and serum Cbl levels can be difficult to interpret.To identify unique clinical or laboratory features among PN patients examine role testing metabolite in identification deficiency.Cohort survey comparing cryptogenic identified during 2-year period. Cobalamin was diagnosed using low elevated methylmalonic acid homocysteine levels.Academic neuromuscular...
We performed a randomized, double-blind phase I clinical trial for six months on the effects of oral L-serine in patients with ALS. The protocol called enrollment diagnosis probable or definite ALS, age 18–85 years, disease duration less than three years and forced vital capacity (FVC) ≥ 60%. Patients were randomly assigned to four different twice-daily dose regimens (0.5, 2.5, 7.5, 15 g/dose). Blood, urine CSF samples, ALS Functional Rating Scale-Revised (ALSFRS-R) scores obtained...
Inclusion-body myositis (IBM) is an inflammatory muscle disease that has proven resistant to treatment. Tumor necrosis factor molecules have been detected in biopsies from patients with IBM. Etanercept a TNFα receptor fusion protein binds and inactivates tumor factor. Nine were treated etanercept at dose of 25 mg, two times week for average 17 ± 6.1 months. Each patient was evaluated using quantitative strength testing. Their data compared different control groups. The first group consisted...
Abstract Introduction Causes of small‐fiber peripheral neuropathies (SFN) are often undefined. In this study we investigated associations serum autoantibodies, immunoglobulin G (IgG) vs fibroblast growth factor receptor‐3 (FGFR‐3), and M (IgM) trisulfated heparan disaccharide (TS‐HDS) in cryptogenic SFN. Methods One hundred fifty‐five patients with biopsy‐proven SFN no identified cause for their neuropathy were blindly tested IgM TS‐HDS IgG FGFR‐3. Results Forty‐eight percent had antibodies,...
Combining agents with different mechanisms of action may be necessary for meaningful results in treating ALS. The combinations minocycline-creatine and celecoxib-creatine have additive effects the murine model. New trial designs are needed to efficiently screen growing number potential neuroprotective agents. Our objective was assess two drug ALS using a novel phase II design. We conducted randomized, double-blind selection sequential pools 60 patients. Participants received minocycline (100...
Genetic factors have been suggested to be involved in the pathogenesis of sporadic inclusion body myositis (sIBM). Sequestosome 1 (SQSTM1) and valosin-containing protein (VCP) are 2 key genes associated with several neurodegenerative disorders but yet thoroughly investigated sIBM. A candidate gene analysis was conducted using whole-exome sequencing data from 181 sIBM patients, whole-transcriptome expression performed patients genetic variants interest. We identified 6 rare missense SQSTM1...
Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients amyotrophic lateral sclerosis (ALS).We performed randomized, double-blind, placebo-controlled trial of 80 ALS participants enrichment the placebo group historical controls (n = 177) at 10 centers United States. Participants were randomized 3:1 ratio to 2 mg/day rasagiline or placebo. The primary outcome was average slope decline on Functional Rating Scale-Revised (ALSFRS-R). Secondary...
<h3>Importance</h3> Cryptogenic sensory polyneuropathy (CSPN) is a common generalized slowly progressive neuropathy, second in prevalence only to diabetic neuropathy. Most patients with CSPN have significant pain. Many medications been tried for pain reduction CSPN, including antiepileptics, antidepressants, and sodium channel blockers. There are no comparative studies that identify the most effective medication CSPN. <h3>Objective</h3> To determine which (pregabalin, duloxetine,...
<h3>Background</h3> Quality of life (QoL) assessment allows healthcare professionals to appreciate the patient perspective their disease. This can help us make a better choice from among various ways we currently measure severity muscle disease such as inclusion body myositis (IBM). However, cannot assume that QoL in IBM is just related psychosocial factors may play an important role determining QoL. <h3>Methods</h3> Sixty subjects with had assessments and concurrent mood using Short-Form 36...
Rasagiline, a monoamine oxidase B inhibitor, slowed disease progression in the SOD1 mouse, and case series of patients with amyotrophic lateral sclerosis (ALS). Here we determine whether rasagiline is safe effective ALS compared to historical placebo controls, it alters mitochondrial biomarkers. We performed prospective open-label, multicenter screening trial 36 treated 2 mg oral daily for 12 months. Outcomes included slope deterioration revised Functional Rating Scale (ALSFRS-R), adverse...